ENDOK S.R.L

What ENDOK S.R.L does

ENDOK S.R.L is a Rome-based pharmaceutical startup incorporated in March 2022 and controlled by TrustPartners Management Consulting, operating in the women's health and endometriosis therapeutics niche. The company develops and sells nutraceutical supplements built on a proprietary, internationally patented blend called EndoGen® — a formulation combining parsley (Petroselinum crispum), rosemary (Rosmarinus officinalis), and celery (Levisticum officinale) extracts with vitamins and selenium, designed to modulate inflammatory and oxidative-stress mechanisms associated with endometriosis. Its lead product MetrioFen® capsules launched in May 2024, followed by MetrioFen® Probiotic (15 billion live cells from patented strains developed with university researchers). The company's research base spans over 20 years of prior work by TrustPartners, an Italian patent (2019), and international patents covering Europe, the United States, Australia, Japan, Mexico, and Russia (2019–2022).

The business model combines direct-to-consumer e-commerce through its own storefront at metriofen.com with B2B distribution via pharmacies, wholesalers, and international distributors across Italy, Germany, France, Austria, and Switzerland. Revenue mechanics are primarily one-time product sales, with no disclosed subscription or recurring layer. Customers are segmented into women of reproductive age with endometriosis (primary), women with fertility challenges including those pursuing medically assisted reproduction, healthcare professionals (gynecologists and medical informers) reached through a reserved professional area with scientific documentation and training, and pharmacy/wholesale buyers in five European markets.

The company pursues a content-led go-to-market strategy anchored by an educational blog, a newsletter funnel, a LinkedIn presence, and earned media partnerships with AOGOI and L'Altra Medicina Magazine. A 35-patient clinical trial across 7 Italian medical centers concluded in October 2025 (NCT07228975) reported 71% pain-reduction efficacy, 52% average reduction in maximum pain intensity, 68% quality-of-life improvement, and 88% patient satisfaction, with full peer-reviewed publication planned for 2026. Headcount is 1–10 employees, revenue is undisclosed, and the only funding event reported is the 2023 Brevetti+ non-dilutive grant from Invitalia.

Name

ENDOK S.R.L

Legal name

ENDOK S.R.L

Website

https://endok.eu

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

ENDOK S.R.L is a Rome-based pharmaceutical startup that develops and sells the patented MetrioFen® nutraceutical line for women with endometriosis and fertility challenges, distributing via D2C e-commerce and pharmacy/wholesale channels across five European countries.

Ownership category

akta.pro rank

Product category

Nutraceutical Supplements for Women's Health

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro industry

PRIMARYCRADAGAF

Probiotics & Digestive Health Supplements

Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Vitamins, Supplements & Sports Nutrition

Keywords

• Endometriosis treatment
• Nutraceutical supplements
• Women's health products
• Probiotic supplements
• Integrated medicine

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

1. Direct-to-Consumer Nutraceutical Sales: EndOK generates revenue through the direct sale of its nutraceutical products (MetrioFen® capsules and MetrioFen® Probiotic) to end consumers via its own e-commerce platform (metriofen.com) and through pharmacies and wholesalers. The company also serves grossists, pharmacists, and foreign distributors as B2B customers.
2. B2B / Wholesale Distribution: Revenue is generated from sales to pharmacies, wholesalers, and international distributors. The products are registered and can be sold in Italy, Germany, France, Austria, and Switzerland.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

ENDOK S.R.L develops, manufactures and sells nutraceutical supplements for women with endometriosis. Its lead product MetrioFen® is a capsule food supplement based on the proprietary patented EndoGen® blend of parsley (Petroselinum crispum), rosemary (Rosmarinus officinalis) and celery (Levisticum officinale) extracts, enriched with vitamins and selenium, designed to reduce inflammation and pain associated with endometriosis. The company also markets MetrioFen® Probiotico, a probiotic supplement containing 15 billion live cells developed with university researchers, and distributes its products via its own e-commerce site, pharmacies, wholesalers and international distributors.

Product overview

ENDOK S.R.L is a pharmaceutical startup based in Rome, Italy, focused on women's health and specifically the treatment of endometriosis. The company offers a product portfolio centered on MetrioFen®, a nutraceutical supplement based on the proprietary EndoGen® blend combining plant extracts (parsley, rosemary, celery), vitamins (B6, D, E), and selenium. MetrioFen® is designed to reduce inflammation and pain associated with endometriosis. Additionally, MetrioFen® Probiotico provides probiotic support with 15 billion live cells targeting female reproductive wellness. The products are developed based on over 20 years of research and international patents, adopting an integrated medicine approach using natural substances.

Differentiator

Problem solved

Functional benefit

Brands

• MetrioFen: Nutraceutical supplement for endometriosis symptoms, based on the proprietary EndoGen® blend. Available in capsules.
• MetrioFen Probiotico
• EndoGen

Products and services

• MetrioFen®
• MetrioFen® Probiotico

Quantifiable outcome

• Reduction in maximum pain intensity: 52% average
• +6 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Leading multinational biological analysis companycoreTechnology or Integration · 1 December 2022EndOK partnered with a leading multinational company specializing in biological analyses to conduct in-vitro preclinical tests on the proprietary mixture directly on endometrial cells. The tests confirmed significant and unexplored therapeutic potential of the blend on proliferation and inflammatory mechanisms of endometrial cells.
• AbbVieminorOthersAbbVie is listed among the pharmaceutical companies that TrustPartners (EndOK's controlling company) has worked with, indicating a historical relationship within the broader consulting portfolio. No specific product or commercial partnership between EndOK and AbbVie is described.
• PfizerminorOthersPfizer is listed among the pharmaceutical companies that TrustPartners has worked with. This represents a historical consulting relationship reference rather than an active commercial partnership with EndOK.
• TakedaminorOthersTakeda is listed among the pharmaceutical companies that TrustPartners has worked with. Represents a historical consulting client reference within the TrustPartners portfolio.
• RocheminorOthersRoche is listed among the pharmaceutical companies that TrustPartners has worked with. Represents a historical consulting client reference.
• SeagenminorOthersSeagen (now part of Pfizer) is listed among the pharmaceutical companies TrustPartners has worked with. Historical consulting client reference.
• NovartisminorOthersNovartis is listed among the pharmaceutical companies TrustPartners has worked with. Historical consulting client reference.
• University researchers (collaborative formulation)coreStrategic or Co-development PartnerEndOK developed the MetrioFen® Probiotic formulation in collaboration with university researchers. The probiotic strains are selected and patented with specific studies on female reproductive system well-being and anti-chlamydial properties. This academic collaboration underpins the scientific credibility of the probiotic product.
• Dr. Monica PerottiminorStrategic or Co-development PartnerDr. Monica Perotti is a medical expert who authored educational content on endometriosis for EndOK, in collaboration with L'Altra Medicina Magazine. She contributed the detailed scientific article 'Endometriosi: una malattia complessa tra infiammazione, dolore e qualità della vita' published on the EndOK blog, lending medical credibility to the company's educational content.
• L'Altra Medicina MagazineminorGTM or Marketing PartnerL'Altra Medicina Magazine is EndOK's media partner for endometriosis educational content. The collaboration produced the detailed article on endometriosis complexity, increasing EndOK's reach and credibility among natural medicine and women's health audiences.
• AOGOI (Associazione Ostetrici Ginecologi Ospedalieri Italiani)minorGTM or Marketing PartnerAOGOI, the Italian Association of Hospital Obstetric Gynecologists, is referenced as a source for endometriosis statistics and guideline information. EndOK contributed articles to AOGOI's endometriosis initiative platform, including content on 'Endometriosi e infiammazione' and 'Endometriosi e Disbiosi Intestinale', establishing medical credibility through association with a leading professional body.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Theramex: Theramex is a global specialty women's health pharmaceutical company offering treatments across contraception, menopause, fertility and gynecological conditions. Comparable as an established branded women's-health player whose portfolio decisions and physician engagement set the competitive context for EndOK's go-to-market.
• AbbVie / Neurocrine Biosciences: AbbVie (with Neurocrine Biosciences) markets Orilissa (elagolix) and Oriahnn, the leading oral GnRH antagonist therapies for endometriosis. As the prescription benchmark in EndOK's target indication, they set the efficacy and payer-reimbursement bar that any endometriosis-focused company — including EndOK — must address.
• Astellas Pharma: Astellas is a Japanese global pharmaceutical company with established women's health and gynecology assets. Comparable because its international patent footprint and gynecological portfolio overlap with EndOK's patent jurisdictions (Japan included) and endometriosis-adjacent therapeutic areas.
• Organon & Co. Organon is a global women's health company spun out of Merck, focused on contraception, fertility, menopause and gynecological therapies. Comparable as a broad incumbent that competes for physician mind-share and patient awareness in endometriosis and adjacent indications.
• Gedeon Richter: Gedeon Richter is a Hungarian-headquartered European pharmaceutical company with a large women's health franchise including products for endometriosis and hormone-related conditions. Comparable as a regional incumbent operating across many of the same European markets EndOK is entering.
• Bayer (Women's Health): Bayer markets Visanne (dienogest) and co-markets Orilissa (elagolix) with Neurocrine for endometriosis pain, making it the dominant incumbent pharmaceutical player in EndOK's exact indication. Comparable because it defines the prescription standard against which EndOK's nutraceutical must position, even though Bayer operates at vastly larger scale.
• Sumitomo Pharma (Myovant Sciences): Sumitomo acquired Myovant Sciences, which markets Myfembree (relugolix combination) for endometriosis-associated pain. Directly comparable as a leading branded endometriosis therapy targeting the same patient population EndOK serves with a non-prescription alternative.

Direct peers

• Lo.Li. Pharma International: Lo.Li. Pharma International is an Italian specialty pharmaceutical company focused on gynecology, endocrinology and reproductive health, marketing branded prescription and supplement products in women's health. As a fellow Italian women-health player with a similar size and product-portfolio mix, it is one of the closest direct comparables for EndOK.
• Schwabe Pharma: Schwabe Group (Dr. Willmar Schwabe) is a major German plant-based pharmaceutical company specializing in evidence-based botanical medicines, including gynecological indications. EndOK's own reserved-area copy explicitly references the 'Schwabe world' for healthcare professionals, suggesting an active commercial/scientific relationship and confirming strong comparability on plant-based, clinically validated women's health products.

Emerging players

• Ovafit: Ovafit is a German/DACH direct-to-consumer women's health supplements brand focused on cycle, fertility and hormonal balance. Comparable as a smaller, digitally native women's nutraceutical brand competing for the same end-consumer in overlapping European markets, though without endometriosis-specific clinical positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/endok-eu

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENDOK S.R.L